Annual CFO
-$6.43 M
-$517.10 K-8.74%
December 1, 2023
Summary
- As of March 13, 2025, BRTX annual cash flow from operations is -$6.43 million, with the most recent change of -$517.10 thousand (-8.74%) on December 1, 2023.
- During the last 3 years, BRTX annual CFO has fallen by -$4.47 million (-227.35%).
- BRTX annual CFO is now -781.82% below its all-time high of -$729.20 thousand, reached on December 31, 2010.
Performance
BRTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$1.70 M
+$165.60 K+8.88%
September 1, 2024
Summary
- As of March 13, 2025, BRTX quarterly cash flow from operations is -$1.70 million, with the most recent change of +$165.60 thousand (+8.88%) on September 1, 2024.
- Over the past year, BRTX quarterly CFO has dropped by -$520.20 thousand (-44.11%).
- BRTX quarterly CFO is now -518.94% below its all-time high of -$274.60 thousand, reached on September 30, 2011.
Performance
BRTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$7.47 M
-$520.20 K-7.48%
September 1, 2024
Summary
- As of March 13, 2025, BRTX TTM cash flow from operations is -$7.47 million, with the most recent change of -$520.20 thousand (-7.48%) on September 1, 2024.
- Over the past year, BRTX TTM CFO has dropped by -$1.01 million (-15.68%).
- BRTX TTM CFO is now -779.00% below its all-time high of -$849.90 thousand, reached on March 31, 2011.
Performance
BRTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
BRTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -8.7% | -44.1% | -15.7% |
| 3 y3 years | -227.3% | -48.4% | -124.3% |
| 5 y5 years | -26.0% | -48.4% | -124.3% |
BRTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -93.1% | at low | -48.4% | +28.6% | -124.3% | at low |
| 5 y | 5-year | -227.3% | +7.1% | -304.3% | +28.6% | -280.3% | at low |
| alltime | all time | -781.8% | +7.1% | -518.9% | +28.6% | -779.0% | at low |
BioRestorative Therapies Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.70 M(-8.9%) | -$7.47 M(+7.5%) |
| Jun 2024 | - | -$1.87 M(-19.5%) | -$6.95 M(+9.1%) |
| Mar 2024 | - | -$2.32 M(+46.0%) | -$6.37 M(-1.0%) |
| Dec 2023 | -$6.43 M(+8.7%) | -$1.59 M(+34.6%) | -$6.43 M(-0.4%) |
| Sep 2023 | - | -$1.18 M(-8.1%) | -$6.46 M(-4.0%) |
| Jun 2023 | - | -$1.28 M(-46.1%) | -$6.73 M(+0.5%) |
| Mar 2023 | - | -$2.38 M(+47.3%) | -$6.70 M(+13.3%) |
| Dec 2022 | -$5.91 M(+77.6%) | -$1.62 M(+11.3%) | -$5.91 M(+8.6%) |
| Sep 2022 | - | -$1.45 M(+16.0%) | -$5.44 M(+17.8%) |
| Jun 2022 | - | -$1.25 M(-21.5%) | -$4.62 M(+12.4%) |
| Mar 2022 | - | -$1.59 M(+39.3%) | -$4.11 M(+23.5%) |
| Dec 2021 | -$3.33 M(+69.5%) | -$1.15 M(+81.9%) | -$3.33 M(+20.8%) |
| Sep 2021 | - | -$629.40 K(-15.2%) | -$2.76 M(+4.0%) |
| Jun 2021 | - | -$741.80 K(-8.8%) | -$2.65 M(+13.8%) |
| Mar 2021 | - | -$813.70 K(+42.2%) | -$2.33 M(+18.6%) |
| Dec 2020 | -$1.96 M(-71.6%) | -$572.10 K(+9.4%) | -$1.96 M(-38.7%) |
| Sep 2020 | - | -$523.10 K(+24.4%) | -$3.20 M(-27.0%) |
| Jun 2020 | - | -$420.40 K(-6.3%) | -$4.39 M(-18.5%) |
| Mar 2020 | - | -$448.60 K(-75.2%) | -$5.39 M(-22.1%) |
| Dec 2019 | -$6.92 M(+35.5%) | -$1.81 M(+5.9%) | -$6.92 M(+3.9%) |
| Sep 2019 | - | -$1.71 M(+20.7%) | -$6.66 M(+5.7%) |
| Jun 2019 | - | -$1.42 M(-28.4%) | -$6.30 M(+6.4%) |
| Mar 2019 | - | -$1.98 M(+27.5%) | -$5.93 M(+16.1%) |
| Dec 2018 | -$5.10 M(+32.5%) | -$1.55 M(+14.8%) | -$5.10 M(+3.9%) |
| Sep 2018 | - | -$1.35 M(+30.0%) | -$4.91 M(+20.7%) |
| Jun 2018 | - | -$1.04 M(-10.2%) | -$4.07 M(+7.2%) |
| Mar 2018 | - | -$1.16 M(-14.8%) | -$3.79 M(-1.6%) |
| Dec 2017 | -$3.85 M | -$1.36 M(+167.0%) | -$3.85 M(+8.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | -$509.20 K(-33.5%) | -$3.56 M(-16.4%) |
| Jun 2017 | - | -$766.00 K(-37.2%) | -$4.25 M(-5.6%) |
| Mar 2017 | - | -$1.22 M(+14.8%) | -$4.50 M(-10.0%) |
| Dec 2016 | -$5.00 M(+60.2%) | -$1.06 M(-11.9%) | -$5.00 M(+0.2%) |
| Sep 2016 | - | -$1.21 M(+18.5%) | -$5.00 M(+14.2%) |
| Jun 2016 | - | -$1.02 M(-40.8%) | -$4.37 M(+5.0%) |
| Mar 2016 | - | -$1.72 M(+63.0%) | -$4.17 M(+33.4%) |
| Dec 2015 | -$3.12 M(-3.3%) | -$1.05 M(+80.6%) | -$3.12 M(+15.5%) |
| Sep 2015 | - | -$583.60 K(-27.9%) | -$2.70 M(-8.5%) |
| Jun 2015 | - | -$809.60 K(+20.0%) | -$2.95 M(-4.6%) |
| Mar 2015 | - | -$674.80 K(+6.4%) | -$3.10 M(-4.1%) |
| Dec 2014 | -$3.23 M(+20.8%) | -$634.30 K(-23.9%) | -$3.23 M(-3.9%) |
| Sep 2014 | - | -$833.70 K(-12.5%) | -$3.36 M(+13.5%) |
| Jun 2014 | - | -$953.20 K(+18.2%) | -$2.96 M(+9.3%) |
| Mar 2014 | - | -$806.70 K(+5.6%) | -$2.71 M(+1.3%) |
| Dec 2013 | -$2.67 M(-16.1%) | -$763.80 K(+75.8%) | -$2.67 M(-10.7%) |
| Sep 2013 | - | -$434.40 K(-38.2%) | -$2.99 M(-0.5%) |
| Jun 2013 | - | -$702.50 K(-9.0%) | -$3.01 M(-15.6%) |
| Mar 2013 | - | -$771.80 K(-28.7%) | -$3.56 M(+11.9%) |
| Dec 2012 | -$3.18 M(+13.3%) | -$1.08 M(+140.1%) | -$3.18 M(-1.0%) |
| Sep 2012 | - | -$450.90 K(-64.1%) | -$3.22 M(+5.8%) |
| Jun 2012 | - | -$1.26 M(+219.0%) | -$3.04 M(+29.1%) |
| Mar 2012 | - | -$393.90 K(-64.7%) | -$2.35 M(-16.2%) |
| Dec 2011 | -$2.81 M(+285.5%) | -$1.12 M(+306.2%) | -$2.81 M(+65.8%) |
| Sep 2011 | - | -$274.60 K(-51.9%) | -$1.70 M(+19.3%) |
| Jun 2011 | - | -$570.80 K(-32.8%) | -$1.42 M(+67.2%) |
| Mar 2011 | - | -$849.90 K | -$849.90 K |
| Dec 2010 | -$729.20 K | - | - |
FAQ
- What is BioRestorative Therapies annual cash flow from operations?
- What is the all time high annual CFO for BioRestorative Therapies?
- What is BioRestorative Therapies annual CFO year-on-year change?
- What is BioRestorative Therapies quarterly cash flow from operations?
- What is the all time high quarterly CFO for BioRestorative Therapies?
- What is BioRestorative Therapies quarterly CFO year-on-year change?
- What is BioRestorative Therapies TTM cash flow from operations?
- What is the all time high TTM CFO for BioRestorative Therapies?
- What is BioRestorative Therapies TTM CFO year-on-year change?
What is BioRestorative Therapies annual cash flow from operations?
The current annual CFO of BRTX is -$6.43 M
What is the all time high annual CFO for BioRestorative Therapies?
BioRestorative Therapies all-time high annual cash flow from operations is -$729.20 K
What is BioRestorative Therapies annual CFO year-on-year change?
Over the past year, BRTX annual cash flow from operations has changed by -$517.10 K (-8.74%)
What is BioRestorative Therapies quarterly cash flow from operations?
The current quarterly CFO of BRTX is -$1.70 M
What is the all time high quarterly CFO for BioRestorative Therapies?
BioRestorative Therapies all-time high quarterly cash flow from operations is -$274.60 K
What is BioRestorative Therapies quarterly CFO year-on-year change?
Over the past year, BRTX quarterly cash flow from operations has changed by -$520.20 K (-44.11%)
What is BioRestorative Therapies TTM cash flow from operations?
The current TTM CFO of BRTX is -$7.47 M
What is the all time high TTM CFO for BioRestorative Therapies?
BioRestorative Therapies all-time high TTM cash flow from operations is -$849.90 K
What is BioRestorative Therapies TTM CFO year-on-year change?
Over the past year, BRTX TTM cash flow from operations has changed by -$1.01 M (-15.68%)